Implications of Rescheduling - Podcast
This quarter two seismic shifts occurred in the United States and Germany with a common denominator: the DEA advanced the rescheduling of cannabis from a narcotic to a Class III drug in the USA, and Germany completed the rescheduling with passage of the Cannabis Reform Law April 1. However, the implications are different for the two largest cannabis markets.
Join us for a fireside chat with Arthur de Cordova, a former Country Manager for AstraZeneca in Europe, and CEO of Ziel.